Literature DB >> 2574077

Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.

M P Goren1, C B Pratt, M J Viar.   

Abstract

The nephrotoxic effects of ifosfamide were assessed in 18 children and adolescents given cumulative doses of 32-112 g/m2 (1.6 g/m2 per day in sequential 5-day courses) with the uroprotectant mesna (1.2 g/m2 per day). Tubular nephrotoxicity was evaluated by measuring the urinary concentrations of N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), and total protein before and during sequential courses of therapy. Of 15 patients who had normal levels of tubular markers before ifosfamide therapy, only 1 developed a persistent increase in baseline values of the three tubular markers with the sixth course of ifosfamide. Although transient increases in the excretion of these markers were observed during each 5-day course of ifosfamide, the magnitude did not increase over sequential courses in these 15 patients. Of the remaining three patients who had increased NAG levels before ifosfamide therapy, two showed a progressive increase in enzymuria and proteinuria, and serum creatinine concentrations increased in a single patient who had obstructive uropathy. Our data suggest that children with normal renal function can be given large cumulative amounts of ifosfamide in fractionated doses with little risk of progressive clinical nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574077     DOI: 10.1007/bf00694342

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Ifosfamide-induced renal tubular defects.

Authors:  W P Patterson; A Khojasteh
Journal:  Cancer       Date:  1989-02-15       Impact factor: 6.860

2.  Unexpected toxicity in patients treated with iphosphamide.

Authors:  J J Van Dyk; H C Falkson; A M Van der Merwe; G Falkson
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

3.  Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.

Authors:  M Hacke; H J Schmoll; J M Alt; K Baumann; H Stolte
Journal:  Clin Physiol Biochem       Date:  1983

4.  Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.

Authors:  G Sangster; S B Kaye; K C Calman; J F Dalton
Journal:  Eur J Cancer Clin Oncol       Date:  1984-03

5.  Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

Authors:  M P Goren; R K Wright; C B Pratt; M E Horowitz; R K Dodge; M J Viar; E H Kovnar
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

Review 6.  Ifosfamide.

Authors:  M Zalupski; L H Baker
Journal:  J Natl Cancer Inst       Date:  1988-06-15       Impact factor: 13.506

7.  Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.

Authors:  G Falkson; J J Van Dyk; R Stapelberg; H C Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.

Authors:  K H Antman; D Montella; C Rosenbaum; M Schwen
Journal:  Cancer Treat Rep       Date:  1985-05

9.  Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.

Authors:  S D Fosså; K Talle
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

10.  Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

Authors:  M P Goren; R K Wright; M E Horowitz; C B Pratt
Journal:  Cancer Treat Rep       Date:  1987-02
View more
  11 in total

1.  Ifosfamide nephrotoxicity in paediatric cancer patients.

Authors:  M S Ashraf; J Brady; F Breatnach; P F Deasy; A O'Meara
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

2.  Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.

Authors:  Takayuki Takimoto; Tasuku Nakabori; Akio Osa; Satomu Morita; Haruko Terada; Susumu Oseto; Takashi Iwazawa; Kinya Abe
Journal:  Int J Clin Oncol       Date:  2011-08-19       Impact factor: 3.402

3.  Progressive renal toxicity due to ifosfamide.

Authors:  D Heney; J Wheeldon; P Rushworth; C Chapman; I J Lewis; C C Bailey
Journal:  Arch Dis Child       Date:  1991-08       Impact factor: 3.791

4.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Authors:  V Gilard; M C Malet-Martino; M de Forni; U Niemeyer; J C Ader; R Martino
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.

Authors:  R M Rossi; C Kist; U Wurster; W R Külpmann; J H Ehrich
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

8.  Renal function in children and adolescents following 72 g/m2 of ifosfamide.

Authors:  C Arndt; B Morgenstern; D Wilson; R Liedtke; J Miser
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 9.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 10.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.